MRKRNasdaqPharmaceutical PreparationsFiscal year ends December 31

Marker Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$1.20+0.16 (+15.38%)

Close on Oct 19, 2026

Market cap: $23.18M
P/E (TTM): –
Dividend yield: –

Marker Therapeutics, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31	FY 2007 2007-12-31	FY 2006 2006-12-31
Revenue	3.55	6.59	3.31	3.51	1.24	0.50	0.21	0.21	0.18	–	–	–	–	–	–	–	–	–	–	–
Research & Development	12	13	10	12	28	19	13	7.95	5.25	3.80	1.71	0.19	0.70	1.06	0.20	0.29	–	–	–	–
General & Administrative	4.18	4.24	7.48	11	13	10	9.98	24	6.41	4.69	4.45	3.18	1.97	1.01	0.31	0.20	–	–	–	–
Operating Expenses	16	18	18	23	41	29	23	148	12	8.49	–	–	–	–	–	–	–	–	–	–
Total Costs & Expenses	–	–	–	–	–	–	–	–	–	–	–	–	–	–	3.32	5.47	–	–	–	–
Operating Income	-13	-11	-15	-20	-39	-29	-23	-148	-11	-8.49	-6.16	-3.37	-2.66	–	-3.32	-5.47	–	–	–	–
Interest & Investment Income	0.59	0.44	0.54	0.25	0.01	0.15	1.08	0.25	0	–	–	–	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	–	–	–	-0.03	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Legal Settlements	–	–	–	–	–	–	–	–	–	–	-0.02	–	–	–	–	–	–	–	–	–
Pretax Income	-12	-11	-14	-20	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Income Tax Expense	-0.02	0.05	0.00	–	–	–	–	0	0	0	0	0	–	–	–	–	–	–	–	–
Income from Continuing Operations	–	-11	-14	-20	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Income from Discontinued Operations	–	–	5.81	-10	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Net Income incl. Noncontrolling Interests	-12	-11	-8.24	-30	-42	-29	-21	-148	–	–	-34	-31	-5.53	–	–	–	–	–	–	–
Net Income	-12	-11	-8.24	-30	-42	-29	-21	-148	-11	-2.46	-34	-31	-5.53	-5.86	-2.03	-3.53	-17	-2.20	-3.89	-1.30
EPS (Basic)(per share)	-0.79	-1.19	-0.94	-3.58	-5.47	-6.10	-4.70	-77.50	-11.60	-3.60	-93.00	-240.00	-584.40	-1,130.40	-4.80	-10.80	–	–	–	–
EPS (Diluted)(per share)	-0.79	-1.19	-0.94	-3.58	-5.47	-6.10	-4.70	-77.50	-11.60	-7.20	-93.00	-240.00	-584.40	-1,130.40	-4.80	-10.80	–	–	–	–
Shares Outstanding (Basic, Weighted)(shares)	15	8.98	8.81	8.35	7.65	4.70	4.56	1.91	0.95	0.69	0.37	0.13	0.01	–	–	–	–	–	–	–
Shares Outstanding (Diluted, Weighted)(shares)	15	8.98	8.81	8.35	7.65	4.70	4.56	1.91	0.95	0.74	0.37	0.13	0.01	–	–	–	–	–	–	–
EBITDA	–	–	–	-17	-37	-28	-22	–	–	–	–	–	–	–	–	–	–	–	–	–
Non-Interest Expense	–	–	–	–	–	–	–	–	–	–	–	–	–	6.22	3.32	–	–	–	–	–
Net Investment Income	–	–	–	–	–	–	–	–	–	–	–	–	–	-6.22	-3.32	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: -302.1%
Net margin: -245.5%
Return on equity, FY2025: -68.8%

Financial strength

Current ratio: 6.03
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 468.2%

Valuation

P/E ratio: –
Price to sales: 6.54
Price to book: 1.91
Dividend yield: –